Cathie Wood's Ark Adds Over $19M Worth Of Moderna Shares After Thursday's 21% Plunge On Guidance Cut
Cathie Wood's Ark Adds Over $19M Worth Of Moderna Shares After Thursday's 21% Plunge On Guidance Cut
COVID-19 vaccine maker Moderna, Inc. (NASDAQ:MRNA) fell over 21% on Thursday after the company reduced its revenue guidance for the year, citing a highly competitive respiratory vaccine market in the U.S. and weak COVID-19 vaccine sales in Europe.
COVID-19疫苗制造商Moderna，Inc.（NASDAQ：MRNA）由于公司调低全年营业收入指导，称美国竞争激烈的呼吸道疫苗市场和欧洲COVID-19疫苗销售疲软，周四股价下跌超过21%。
What Happened: Moderna stock plunged 21.01% to $94.17 on Thursday and fell an incremental 1.73% to $92.54 in premarket trading on Friday, according to Benzinga Pro data.
现代a股在周四下跌了21.01%，至94.17美元，并在周五盘前交易中额外下跌1.73%，至92.54美元，根据Benzinga Pro的数据。
Cathie Wood's Ark Invest capitalized on the weakness and piled into the stock. On Thursday two of Ark's actively managed exchange-traded funds – the Ark Innovation ETF (NYSE:ARKK) and the ARK Genomic Revolution ETF (CBOE: ARKG), bought 202,991 shares of Moderna, valued at $19.12 million.
Cathie Wood的Ark Invest利用这一弱势，押注了这个股票。周四，Ark的两只主动交易型基金 - Ark Innovation ETF（纽交所：ARKK）和ARk Genomic Revolution ETF（CBOE：ARKG）购买了Moderna的202,991股，价值1912万美元。
The buying is in line with Ark's strategy of using any potential weakness as a buying opportunity in its core portfolio holdings.
该购买符合Ark使用其核心投资组合中任何潜在弱势作为购买机会的策略。
Moderna is ARKK's 24th biggest holding in value terms, with the flagship fund holding 736,884 shares valued at $69.39 million. ARKG holds 399,287 Modena shares valued at $37.60 million.
现代a股是ARKK价值排名第24大的持股，旗舰基金持有736,884股，价值6939万美元。 ARKG持有399,287股Modena的股份，价值3760万美元。
Why It's Important: Moderna, which is one of the pioneers of the mRNA new-vaccine technology, was among the frontrunners that launched vaccines for the virus causing the COVID-19 pandemic. The early-mover advantage has helped the company to make outsized profits from selling the vaccine.
为什么这很重要：Moderna是核糖核酸（mRNA）新疫苗技术的先驱之一，是针对导致COVID-19大流行的病毒推出疫苗的领跑者之一。先发优势帮助该公司从出售疫苗中获得了超额利润。
As the pandemic abated, the company has done well to diversify its revenue stream. In late May, it received FDA approval for its respiratory syncytial vaccine. The company is also developing a slew of personalized cancer vaccines in collaboration with Merck & Co. (NYSE:MRK).
随着大流行的消退，该公司在多元化营收渠道方面表现出色。5月下旬，它获得了呼吸道合胞病毒疫苗的FDA批准。该公司还与Merck＆Co.（纽约证券交易所：MRK）合作开发一批个性化癌症疫苗。
- Cathie Wood's Ark Invest Sells $14.7M Worth Of Coinbase Shares And $8.5M Worth Of Palantir Stock — Also Sells Robinhood Shares But Loads Up On AMD
- 凯瑟琳·伍德的Ark投资公司出售了价值1470万美元的Coinbase股份和价值850万美元的palantir股票-还出售了Robinhood股份，但增持了AMD股份
Photo via Wikimedia Commons
照片通过Wikimedia Commons